Upcoming Events

William Blair 9th Annual Cancer Immunotherapy Conference
March 20-21, 2019 - Apella Event Space Alexandria Center, New York, NY
ARTEMIS™ Antibody-TCR (AbTCR) T-cell Therapy for Solid and Hematological Malignancies

Past Events

Cowen 39th Annual Health Care Conference
March 11-13, 2019 - Boston Marriott Copley Place, Boston, MA
A Novel T-Cell Engineering Technology (ARTEMIS™) for Strong Clinical Efficacy while Mitigating CRS/Neurotoxicity

Clinical Application of CAR T Cells 2019
March 14-15, 2019 - Zuckerman Research Center, New York, NY
Development of ARTEMIS™ Antibody-TCR (AbTCR) Expressing T Cells Against Solid and Hematological Malignancies with the Potential to Eliminate CRS Risks

CAR-TCR Summit
September 4-7, 2018 – Boston, MA United States
Overcoming Safety Challenges of Genetically Engineered T-Cell Therapy for the Treatment of Cancer

ASCO Annual Meeting
June 1-5, 2018 – McCormick Place, Chicago, Illinois
ET190L1-ARTEMIS™ T cell therapy leads to complete remission of relapsed and refractory (r/r) B-cell lymphoma with no cytokine release syndrome in the first-in-human clinical study

AACR Annual Meeting
April 14-18, 2018 – McCormick Place North/South, Chicago, Illinois
Anti-CD19 ARTEMIS™ T cells prevent excessive inflammatory cytokine release, including IL-6, in a co-culture model of CRS

World Adopt Summit 2017
March 7-9, 2017 – London, United Kingdom
Targeting the "Untargetable" Solid Tumor Antigens

ASH Annual Meeting
December 3-6, 2016 – San Diego, CA United States
Anti-CD19-ARTEMIS™ T cell therapy reduces cytokine release without compromising efficacy against preclinical lymphoma models

CAR-TCR Summit
September 13-16, 2016 – Boston, MA United States
TCR-like CARs targeting intracellular cancer-specific antigens for treatment of solid tumors

Immuno Oncology Summit - Adoptive T Cell Therapy
September 1-2, 2016 – Boston, MA United States
Bispecific T-Cell Engaging Antibody Targeting AFP/MHC Complex for the Treatment of Liver Cancer

CBIS 11th Biennial Conference
July 29-August 2, 2016 – Chengdu, China
Innovating antibody and adoptive T-cell therapies for targeting “undruggable” cancer antigens

June 3-7, 2016 – Chicago, IL United States
Towards a safer CD19 CAR-T therapy with reduced risk of Cytokine Release Syndrome (CRS)

5th Annual Cell Line Development & Engineering Asia Conference
May 17-19, 2016 – Shanghai, China
Assessment of antibody- or cell- mediated cytotoxicity via multiple assay platforms

April 16-20, 2016 – New Orlean, LA United States
ET1402L1-CAR-T therapy targeting alpha-fetoprotein (AFP)-MHCI complex for liver cancer

CAR-T Summit
November 12-13, 2015 – Cambridge, MA United States
First-in-class CAR-T therapy for HCC via targeting an AFP-MHCI complex

4th Annual Cell Line Development & Engineering Asia Conference
May 19-22, 2015 – Shanghai, China
Assessment of antibody Fc mediated effector functions via multiple assay platforms